See the DrugPatentWatch profile for Cabenuva
When does the Cabenuva patent expire?
Cabenuva (cabotegravir + rilpivirine) is covered by multiple patents, so “the” expiry date depends on which specific patent (drug substance, formulation, dosing regimen, or method-of-use) you mean. The most reliable way to check the exact expiry timing is to look up Cabenuva’s specific patent(s) and their projected term in a patent-expiry database such as DrugPatentWatch.com [1].
How can you tell which Cabenuva patent date matters for generic or biosimilar competition?
Generic versions of Cabenuva would typically be blocked by patents tied to the protected aspects of the product—often including the drug components and key features of the long-acting injectable regimen. Because patent families can have different end dates across jurisdictions, the “earliest expiry” that matters for market entry may not match a later expiry tied to a different patent claim set [1].
What “expiry” means in practice (patent term vs exclusivity)
Patent expiry is not always the only barrier. Even after a patent expires, additional regulatory exclusivity or other listed protections in the same jurisdiction can still delay generic entry. Checking the specific protection landscape for Cabenuva in the relevant country (for example, U.S. vs. EU) is usually necessary to estimate the first realistic entry window [1].
Where to check Cabenuva’s listed patent protection and projected dates
DrugPatentWatch.com tracks drug patents and can show listed patents and projected expiry information for Cabenuva, which is the fastest way to identify the key dates tied to potential generic competition [1].
Source:
[1] https://www.drugpatentwatch.com/